Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 7/20 | 0.42 |
| ▸ | BCR | P11274 | 7/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.38 |
| ▸ | CFD | P00746 | 1/20 | 0.37 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416428 | 0.86 | CFD (0.40) | CYP1A2POLBCYP3A4CYP2C19HDAC1 | |
| SCHEMBL16511611 | 0.83 | LMNA (0.58) | POLBLMNANPSR1USP30HDAC8 | |
| SCHEMBL28869484 | 0.83 | LMNA (0.58) | POLBLMNANPSR1USP30HDAC8 | |
| SCHEMBL2373909 | 0.82 | CYP1A2 (0.55) | CYP1A2POLBCYP3A4CYP2C19ABL1 | |
| SCHEMBL2373906 | 0.82 | CYP1A2 (0.55) | CYP1A2POLBCYP3A4CYP2C19ABL1 | |
| SCHEMBL2373009 | 0.80 | CYP1A2 (0.55) | CYP1A2POLBCYP3A4CYP2C19ABL1 | |
| SCHEMBL2373004 | 0.80 | CYP1A2 (0.55) | CYP1A2POLBCYP3A4CYP2C19ABL1 | |
| SCHEMBL16765964 | 0.77 | CYP1A2 (0.49) | CYP1A2POLBCYP3A4CYP2C19ABL1 | |
| SCHEMBL15346388 | 0.74 | CYP1A2 (0.44) | CYP1A2POLBCYP3A4CYP2C19ABL1 | |
| SCHEMBL23885134 | 0.73 | CYP1A2 (0.48) | CYP1A2POLBCYP3A4CYP2C19ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102629-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102629-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2011119860-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119860-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102629-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | C1QBP, BLVRB, RRP1B | CYP1A2 1303/4885POLB 1258/4885CYP3A4 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.